Latisha Heinlen, MD
Rheumatology · Oklahoma City, OKNPI 1649430810
Payments from drug & device makers
Across 2,038 payments — averaging $911.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$600K
- Novartis$534K
- Janssen Scientific Affairs, LLC$116K
- E.r. Squibb & Sons, L.L.C.$101K
- Johnson & Johnson$93K
- Sanofi US Services Inc.$81K
- plus $333K from 24 others
Across 3 payments — averaging $9775.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$29K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 693 | $600,147 |
| Novartis | 84 | $533,918 |
| Janssen Scientific Affairs, LLC | 104 | $115,535 |
| E.r. Squibb & Sons, L.L.C. | 74 | $100,821 |
| Johnson & Johnson | 191 | $92,578 |
| Sanofi US Services Inc. | 16 | $80,832 |
| Amgen(2 entities) | 278 | $72,533 |
| Sanofi | 104 | $66,443 |
| Janssen Research & Development, LLC | 19 | $65,469 |
| Eli Lilly | 2 | $54,412 |
| GSK | 65 | $27,928 |
| Lilly USA, LLC | 62 | $22,937 |
| UCB, Inc. | 157 | $13,674 |
| Gilead | 10 | $6,147 |
| AstraZeneca(2 entities) | 63 | $1,626 |
| Genentech USA, Inc. | 36 | $511 |
| Pfizer | 27 | $367 |
| Aurinia Pharma U.S., Inc. | 9 | $193 |
| Fresenius Kabi USA, LLC | 9 | $172 |
| Sandoz | 7 | $154 |
| Boehringer Ingelheim | 6 | $125 |
| Osiris Therapeutics Inc. | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Organon | 4 | $94 |
| ANI Pharmaceuticals, Inc. | 5 | $94 |
| Bristol Myers Squibb | 4 | $66 |
| Radius Health, Inc. | 4 | $62 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Mylan Institutional Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
How this compares
$1,857,128 in reported general payments places this provider in the 95th percentile of 67 rheumatology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Oklahoma City
- Christine CoddingOklahoma City$2.8M
- Cristina ArriensOklahoma City$1.8M
- Joan MerrillOklahoma City$1.8M
- Mohammad KhanOklahoma City$999K
- Fahed HamadehOklahoma City$321K
- William SchnitzOklahoma City$290K
- Michael PickrellOklahoma City$163K
- John GoetzingerOklahoma City$38K
- Judith JamesOklahoma City$18K
- Robert ArthurOklahoma City$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.